|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
CA2124690C
(en)
|
1992-10-02 |
2007-09-11 |
Thomas Osterberg |
Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
|
|
DE69428813T2
(de)
|
1993-12-28 |
2002-04-04 |
Allergan Sales Inc |
Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
|
|
US5512547A
(en)
|
1994-10-13 |
1996-04-30 |
Wisconsin Alumni Research Foundation |
Pharmaceutical composition of botulinum neurotoxin and method of preparation
|
|
US5756468A
(en)
|
1994-10-13 |
1998-05-26 |
Wisconsin Alumni Research Foundation |
Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
|
|
GB9508204D0
(en)
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
US20030095927A1
(en)
|
1997-10-01 |
2003-05-22 |
Dugger Harry A. |
Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
|
|
EP1053014A4
(en)
|
1998-01-26 |
2004-11-10 |
Univ Massachusetts |
BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE
|
|
TW574036B
(en)
|
1998-09-11 |
2004-02-01 |
Elan Pharm Inc |
Stable liquid compositions of botulinum toxin
|
|
US6358917B1
(en)
*
|
1999-08-24 |
2002-03-19 |
Jean D. A. Carruthers |
Cosmetic use of botulinum toxin for treatment of downturned mouth
|
|
US6544548B1
(en)
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
|
US6844324B1
(en)
|
1999-11-12 |
2005-01-18 |
Massachusetts Institute Of Technology |
Modular peptide mediated intracellular delivery system and uses therefore
|
|
IL149778A0
(en)
|
1999-11-22 |
2002-11-10 |
Universal Preservation Technologies Inc |
Preservation of sensitive biological material
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
DK1398038T4
(da)
|
2000-02-08 |
2011-03-28 |
Allergan Inc |
Lægemidler med botulinustoxin
|
|
US7780967B2
(en)
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US6670322B2
(en)
|
2000-06-01 |
2003-12-30 |
Wisconsin Alumni Research Foundation |
Method of targeting pharmaceuticals to motor neurons
|
|
US20040033241A1
(en)
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US6306423B1
(en)
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
|
US20040220100A1
(en)
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
JP5610659B2
(ja)
*
|
2000-07-21 |
2014-10-22 |
ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
多成分生物学的輸送システム
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US6787517B1
(en)
*
|
2000-12-29 |
2004-09-07 |
Allergan, Inc. |
Agent and methods for treating pain
|
|
WO2003000193A2
(en)
|
2001-06-21 |
2003-01-03 |
Surromed, Inc. |
Covalent coupling of botulinum toxin with polyethylene glycol
|
|
CN101721362B
(zh)
*
|
2002-02-14 |
2018-07-03 |
中外制药株式会社 |
包含抗体的溶液制剂
|
|
US20030224020A1
(en)
|
2002-05-31 |
2003-12-04 |
Zabudkin Alexander F. |
Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
|
|
US20040009180A1
(en)
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
|
US9265725B2
(en)
*
|
2002-10-25 |
2016-02-23 |
Foamix Pharmaceuticals Ltd. |
Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
|
|
US8119109B2
(en)
*
|
2002-10-25 |
2012-02-21 |
Foamix Ltd. |
Foamable compositions, kits and methods for hyperhidrosis
|
|
RU2206337C1
(ru)
|
2002-10-29 |
2003-06-20 |
Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" |
Лекарственный препарат для лечения мышечных дистоний и способ его получения
|
|
US20040086532A1
(en)
|
2002-11-05 |
2004-05-06 |
Allergan, Inc., |
Botulinum toxin formulations for oral administration
|
|
DE10333317A1
(de)
|
2003-07-22 |
2005-02-17 |
Biotecon Therapeutics Gmbh |
Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
|
|
US20100266638A1
(en)
*
|
2004-02-26 |
2010-10-21 |
Allergan, Inc. |
Headache treatment method
|
|
JP2007527431A
(ja)
*
|
2004-03-03 |
2007-09-27 |
ルバンス セラピュティックス |
局所的診断及び治療用の輸送のための組成物及び方法
|
|
US9211248B2
(en)
*
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
BRPI0508410B8
(pt)
*
|
2004-03-03 |
2021-05-25 |
Revance Therapeutics Inc |
composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
|
|
GB2416122A
(en)
*
|
2004-07-12 |
2006-01-18 |
Ipsen Ltd |
Botulinum neurotoxin composition
|
|
EP2266599B1
(en)
*
|
2004-07-26 |
2014-04-16 |
Merz Pharma GmbH & Co. KGaA |
Therapeutic composition with a botulinum neurotoxin
|
|
US20070196364A1
(en)
*
|
2004-07-27 |
2007-08-23 |
Human Genome Sciences, Inc. |
Pharmaceutical Formulation and Process
|
|
WO2006013370A1
(en)
|
2004-08-04 |
2006-02-09 |
Ipsen Limited |
Pharmaceutical composition containing botulinum neurotoxin a2
|
|
EP3210620A1
(en)
|
2004-08-04 |
2017-08-30 |
Ipsen Biopharm Limited |
Pharmaceutical composition containing botulinum neurotoxin a2
|
|
GB2419526A
(en)
*
|
2004-10-28 |
2006-05-03 |
Ipsen Ltd |
Pharmaceutical composition containing botulinum neurotoxin
|
|
US7838011B2
(en)
*
|
2005-02-14 |
2010-11-23 |
Pankaj Modi |
Stabilized protein compositions for topical administration and methods of making same
|
|
US7727537B2
(en)
*
|
2005-02-14 |
2010-06-01 |
Dpm Therapeutics Corp. |
Stabilized compositions for topical administration and methods of making same
|
|
US9314431B2
(en)
*
|
2005-02-14 |
2016-04-19 |
Transdermal Corp |
Solubilized benzoyl small molecule
|
|
ZA200707352B
(en)
*
|
2005-03-03 |
2009-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
US8323666B2
(en)
*
|
2005-08-01 |
2012-12-04 |
Allergan, Inc. |
Botulinum toxin compositions
|
|
US8137677B2
(en)
*
|
2005-10-06 |
2012-03-20 |
Allergan, Inc. |
Non-protein stabilized clostridial toxin pharmaceutical compositions
|
|
US8168206B1
(en)
*
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
CN103126971A
(zh)
*
|
2005-11-17 |
2013-06-05 |
雷文斯治疗公司 |
减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
|
|
US9486408B2
(en)
*
|
2005-12-01 |
2016-11-08 |
University Of Massachusetts Lowell |
Botulinum nanoemulsions
|
|
US7899450B2
(en)
*
|
2006-03-01 |
2011-03-01 |
Telecommunication Systems, Inc. |
Cellular augmented radar/laser detection using local mobile network within cellular network
|
|
US20090123527A1
(en)
*
|
2006-07-24 |
2009-05-14 |
Akorn, Inc. |
Method of inducing topical anesthesia and transdermal patch
|
|
US20080226729A1
(en)
*
|
2006-09-08 |
2008-09-18 |
Becton, Dickinson And Company |
Stable powder formulations of alum-adsorbed vaccines
|
|
SG177184A1
(en)
*
|
2006-12-01 |
2012-01-30 |
Anterios Inc |
Amphiphilic entity nanoparticles
|
|
AU2007234612B2
(en)
*
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
FR2910327B1
(fr)
*
|
2006-12-22 |
2013-04-26 |
Scras |
Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
|
|
CN102988995A
(zh)
*
|
2006-12-29 |
2013-03-27 |
雷文斯治疗公司 |
用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
|
|
GB0700523D0
(en)
*
|
2007-01-11 |
2007-02-21 |
Insense Ltd |
The Stabilisation Of Proteins
|
|
RU2009149604A
(ru)
|
2007-06-01 |
2011-07-20 |
Мерц Фарма Гмбх Унд Ко. Кгаа (De) |
Способ предоставления устойчивого к температуре миорелаксанта на основе нейротоксичного компонента ботулинического токсина в твердой форме
|
|
WO2009008595A1
(en)
*
|
2007-07-10 |
2009-01-15 |
Medy-Tox, Inc. |
Pharmaceutical liquid composition of botulinum toxin with improved stability
|
|
CA2694046C
(en)
*
|
2007-07-26 |
2023-09-12 |
Revance Therapeutics, Inc. |
Cationic peptides and compositions thereof
|
|
WO2009056651A1
(en)
*
|
2007-11-02 |
2009-05-07 |
Cytos Biotechnology Ag |
Angiotensin-carrier formulation
|
|
US9107815B2
(en)
*
|
2008-02-22 |
2015-08-18 |
Allergan, Inc. |
Sustained release poloxamer containing pharmaceutical compositions
|
|
CN105833254A
(zh)
|
2008-12-10 |
2016-08-10 |
阿勒根公司 |
梭菌毒素药物组合物
|
|
HUE037595T2
(hu)
*
|
2008-12-31 |
2018-09-28 |
Revance Therapeutics Inc |
Injektálható botulinum toxin készítmények
|
|
EP2248518B1
(en)
*
|
2009-04-17 |
2013-01-16 |
Merz Pharma GmbH & Co. KGaA |
Formulation for stabilizing proteins, peptides or mixtures thereof.
|
|
IL268980B
(en)
*
|
2009-06-25 |
2022-09-01 |
Revance Therapeutics Inc |
Albumin-free botulinum toxin formulations
|
|
JP5854559B2
(ja)
*
|
2009-07-06 |
2016-02-09 |
ヴァリエーション バイオテクノロジーズ インコーポレイテッド |
小胞を調製する方法及びこれから製造される製剤
|
|
US20110059079A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
|
SI2490986T1
(sl)
*
|
2009-10-21 |
2018-12-31 |
Revance Therapeutics, Inc. |
Metode in sistemi za prečiščenje nekompleksiranega nevrotoksina botulina
|
|
US20110106021A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Revance Therapeutics, Inc. |
Device and Method for Topical Application of Therapeutics or Cosmetic Compositions
|
|
WO2011050468A1
(en)
*
|
2009-10-30 |
2011-05-05 |
Duoject Medical Systems Inc. |
Inter vial transfer system
|
|
WO2012048854A2
(en)
*
|
2010-10-12 |
2012-04-19 |
Merz Pharma Gmbh & Co. Kgaa |
Formulation suitable for stabilizing proteins, which is free of mammalian excipients
|
|
LT2661276T
(lt)
*
|
2011-01-07 |
2017-12-11 |
Revance Therapeutics, Inc. |
Paviršinio naudojimo kompozicija, apimanti botulino toksiną ir dažą
|
|
PL3241547T3
(pl)
*
|
2011-03-31 |
2021-02-08 |
Medy-Tox Inc. |
Liofilizowany preparat toksyny botulinowej
|
|
US20130224268A1
(en)
*
|
2012-02-27 |
2013-08-29 |
Newgen Biopharma Corp. |
Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
|
|
MX370929B
(es)
*
|
2012-10-28 |
2020-01-08 |
Revance Therapeutics Inc |
Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
|
|
GB201407525D0
(en)
*
|
2014-04-29 |
2014-06-11 |
Syntaxin Ltd |
Manufacture of recombinant clostridium botulinum neurotoxins
|
|
EP3590500B1
(en)
|
2014-12-23 |
2025-06-25 |
Merz Pharma GmbH & Co. KGaA |
Botulinum toxin prefilled container
|
|
EP3368071B1
(en)
*
|
2015-10-29 |
2022-01-26 |
ReVance Therapeutics, Inc. |
Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
|
|
FI126979B
(en)
*
|
2016-02-29 |
2017-09-15 |
Faron Pharmaceuticals Oy |
Lyophilized pharmaceutical formulation and its use
|
|
IL262180B2
(en)
*
|
2016-04-12 |
2025-12-01 |
Illustris Pharmaceuticals Inc |
Compositions for topical application of compounds
|
|
PL3463432T3
(pl)
|
2016-05-27 |
2021-04-19 |
Ipsen Biopharm Limited |
Ciekła formulacja neurotoksyny stabilizowana tryptofanem lub tyrozyną
|
|
WO2019046311A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Revance Therapeutics, Inc. |
TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS
|
|
CA3081596A1
(en)
*
|
2017-11-03 |
2019-05-09 |
Revance Therapeutics, Inc. |
Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
|
|
WO2019113133A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Revance Therapeutics, Inc. |
Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
|